The OCMX™ is pleased to announce the listing of Covalent Biosciences Inc. to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

MISSOURI CITY, TX, July 13, 2020 /Neptune100/ — We plan to commercialize the Catalytic Antibody (Catabody) and the catabody-inducing Electrophilic Vaccine (E-Vaccine) technology platforms for high impact medical needs that are difficult if not impossible to meet by conventional approaches. The quest for catabodies dates to Linus Pauling, driven by hope that catabodies will prove to be ‘magic bullets’ for on-demand immune destruction of disease-causing protein targets, free of the intrinsic efficacy and safety limitations of ordinary antibodies.

Our 30 year academic R&D discovered discrete monoclonal catabodies that serve as natural anti-aging and anti-infection defenses, and we invented rational algorithms to induce catabodies using E-vaccines. Together, the R&D generated proof-of-concept for the therapeutic and preventive utility of our technology for Alzheimer and other amyloid diseases, HIV infection, drug-resistant bacteria, and the ever-emerging threat of viruses such as COVID-19 (which is extraordinarily contagious and induces a uniquely dysfunctional ordinary antibody response).

We have unique insight and know-how to bring our technology platform to the market as the basis of more powerful medical interventions compared to conventional approaches, and we are looking for $15.3 Mil capital for implementing the next commercialization steps.

The OCMX™ is pleased to announce the listing of Covalent Biosciences Inc. to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

The OCMX™ has spent considerable time completing its due diligence on Covalent Biosciences Inc. and concluded that there is indeed a tremendous opportunity for Investors and Advisors.

The OCMX™ noted that Covalent Biosciences Inc. exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.


Richard Massey, Co-Founder and CEO

Dr. Richard J. Massey was President and Chief Operating Officer of IGEN International, Inc. (NASDAQ: IGEN), a highly successful biotechnology company, which he co-founded. His extensive experience included managing R&D programs, patents, product development, manufacturing, and business development. Dr. Massey led the quest for catalytic antibodies in industry and was an inventor on multiple patents in the field. He also led the team that discovered the application of electrochemiluminescence for immune and molecular diagnostics that resulted in products that generated multibillion-dollar sales.

He is an inventor on over 200 patents on catalytic antibodies and ECL. Dr. Massey has additional expertise with FDA submissions for diagnostic and therapeutic products. He was responsible for the ISO certification at IGEN and managed programs that resulted in the launch of successful products for the healthcare market in the United States, Europe, and Japan. He also played a significant role in raising over $100 million through the sale of private equity and licensing deals.

Dr. Massey received his doctorate in the field of microbiology from the University of Illinois Medical Center in Chicago. He was a senior scientist at the National Cancer Institute Frederick Cancer Center and a professor at Rush Medical Center in Chicago.

Sudhir Paul, Co-Founder, CSO

Paul’s work as a Professor at the Universities of Nebraska and Texas has brought catabodies/E-vaccines from chemical curiosities to the verge of medical use. His research was funded continuously by the NIH, non-profit foundations and biotech companies since 1983. His early discovery patents were bought out (USD 21 MM) by Abgenix in 2001.

He discovered harmful catabodies in autoimmune disease, progressing to devising our on-demand technology platform for generating catabodies and E-vaccines for disease treatment and prevention. He has authored ~200 original research articles and edited several books. Paul co-founded Covalent Bioscience. In 2018, he moved fulltime to Covalent to translate his know-how and inventions for medical benefits.

He completed his B.Sc. with Honors, Punjab University, India and M.Sc. And Ph.D. (Biochemistry), All-India Institute Medical Sciences.

Prior to his faculty appointments, he held an Alexander von Humboldt Fellowship at the University of Kiel, West Germany.

Stephanie Planque, Co-Founder, Principle Scientist

Planque was awarded the Ph.D. degree in 2009 by the University of Texas-Houston Medical School for her advances in applying electrophilic analogs of proteins to decipher the beneficial and harmful functional effects of catabodies.

She then expanded her focus to vaccination and therapeutic catabody identification using proprietary electrophilic target analogs. Her work was published in 49 peer-reviewed scientific articles, she has numerous national/international conference presentations, and she was PI in an NIH-funded STTR grant. She moved fulltime as a co-founder to Covalent in 2018 to focus on rapidly translating our electrophilic vaccine/catabody technologies to clinical reality.

She developed the Catabody and E-Vaccine Technology over 20 years and over 49 peer-reviewed articles throughout her carrier.


The OCMX™ is literally changing how companies and investment funds generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.

The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.

Contact Us
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]